Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL

NCT02187354 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia

Interventions

DRUG: Blinatumomab
OTHER: Extension of LTFU as per ProtocolAmendment7 7Jun18

Sponsor

Amgen